Patrick Soon-Shiong: Revolutionary or Manipulator of Science?
In this article
In recent months, the same face and the same message have appeared repeatedly on social media and science communication platforms. Patrick Soon-Shiong , a physician and entrepreneur, claims that a “major blind spot” in cancer treatment has been overlooked for decades:
These claims are presented particularly alongside a protocol called “Cancer Bioshield” (Cancer Bio-Shield) and IL-15-based immune therapies. But is this a revolution, or “science fiction” grounded in strong science but embellished with commercial goals?
1. First, an Introduction: Who Is Patrick Soon-Shiong?
Let us first be clear: Patrick Soon-Shiong is not a fraudulent figure or a charlatan. He is a scientist with high academic and industry credibility who has made real contributions to modern oncology.
- Inventor of Abraxane: He developed nab-paclitaxel , now a standard treatment for breast, pancreatic and lung cancers.
- Billionaire Entrepreneur: He is one of the world’s wealthiest doctors. He is the founder of ImmunityBio and the owner of the Los Angeles Times newspaper.
2. Solid Scientific Ground: What Does He Get Right?
The foundation of Soon-Shiong’s narrative rests on facts accepted by modern immunology.
Lymphopenia (Low lymphocyte count): A reduction in T cells, our soldiers in the fight against cancer. Hundreds of studies over the past 20 years (e.g., Ray-Coquard et al.) have demonstrated shorter survival in patients with low lymphocyte counts at the start of treatment. This is an established fact in oncology.
The previously used cytokine IL-2 was highly toxic. IL-15, however, increases the immune system’s “Natural Killer” (NK) and “Fighter” (CD8+ T) cells without stimulating its braking mechanisms (Treg). The IL-15 superagonist (ANKTIVA) developed by Soon-Shiong’s company received FDA approval for bladder cancer in 2024. Thus, the drug and its mechanism are real.
3. The Turning Point: From Science to “Marketing”
Problems arise when scientific facts begin to be presented as a commercial “recipe for salvation.”
The person identifying the problem is also selling the drug. While drawing attention to lymphopenia, Soon-Shiong points to products from his own company, ImmunityBio, as the solution. Moreover, “Cancer Bioshield” (Cancer Bio-Shield) is a brand name that offers patients hope, rather than a scientific term.
This statement is a dangerous generalization. Lymphopenia is a biomarker (indicating the course of disease), but it is not the sole cause of cancer. Thousands of patients with low lymphocyte counts benefit from treatment. Saying “If we fix immunity, cancer will definitely disappear” oversimplifies and denies the complexity of cancer biology.
What Is the Level of Evidence?
Most of the data presented come from “single-arm” studies or “case stories.” The comparative (randomized) Phase 3 results involving thousands of patients that are needed to change standard treatment are not yet available.
4. What Is the World Saying? (Media and Criticism)
Patrick Soon-Shiong is frequently portrayed as a “controversial” figure in the US media. Here are the main criticisms:
- Criticism From STAT News & Politico: In 2017-2018, substantial articles were published alleging that Soon-Shiong used his “Cancer Moonshot 2020” project as a “marketing tool” rather than a scientific breakthrough.
- The Culture of “Hype”: Critics emphasize the risk that Soon-Shiong may manipulate share values and patient expectations by presenting early-stage data as “established revolutions” (Science by Press Release).
- Definition: The scientific community uses the term "Scientist-entrepreneur with narrative bias" for such figures—scientists and entrepreneurs with a biased narrative. In other words, they are not lying, but are bending the truth to lead toward their own products.
Scientific References and Further Reading
- Lymphopenia and Prognosis: Ray-Coquard I, et al. "Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas." Cancer Research, 2009. (Foundational study demonstrating the association between lymphopenia and poor outcomes in cancer).
- IL-15 Mechanism: Waldmann TA. "The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design." Nature Reviews Immunology, 2006. (Foundational review explaining the difference between IL-2 and IL-15).
- ANKTIVA (N-803) Approval: Chamie K, et al. "IL-15 Superagonist N-803 Plus BCG in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer." NEJM Evidence, 2023. (Clinical study demonstrating the success of Soon-Shiong’s drug).
- Critical Reading (English): "The Story of Patrick Soon-Shiong" - STAT News & Politico archives (Analyses of the relationship between biotechnology and the media).
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.
Revolutionary or Manipulator?
The answer is not black and white. Patrick Soon-Shiong is a visionary scientist with real contributions to oncology. His warnings about IL-15 and lymphopenia are scientifically justified and deserve attention.
However, treatments presented in polished packages such as "Cancer Bioshield" are not yet “standard treatment.” In science, revolutions are declared through randomized clinical trials, rather than social media videos or brand names.
In Conclusion: What Soon-Shiong describes is an “as-yet-unproven hypothesis,” rather than a “lie.” It offers hope for our patients, but for now should not be seen as a miracle that will replace standard treatments. Science requires patience; every major claim must be tested with data.